Merck (MRK) stock price slips into the weekend — what investors watch next week
Merck & Co shares ended Friday down 0.92%, closing at $108.18. In after-hours trading, the stock slipped slightly to $107.91.
Pfizer stock slips on ex-dividend day — what to watch ahead of Feb. 3 earnings
Pfizer shares dropped roughly 1.9% to $25.62 Friday afternoon, underperforming the health-care sector as the stock went ex-dividend. The Health Care Select Sector SPDR Fund dipped about 0.5%, while the SPDR S&P 500 ETF Trust inched up around 0.1%. Merck slipped about 1%, and Moderna tumbled over 7%. Trading volume for Pfizer hit roughly 24.8 million shares.
Moderna stock slides nearly 6% as CEO flags pullback in Phase III vaccine trials
Moderna shares slipped 5.8%, hitting $48.88 by midday Friday, after fluctuating between $46.86 and $50.95 earlier. Roughly 10.9 million shares traded hands.
Moderna (MRNA) stock jumps after-hours as CEO signals pullback in new vaccine trials
Moderna shares surged 4.2% to $51.87 in after-hours trading Thursday, following an earlier jump of about 11% to $55.17 on heavy volume—more than 34 million shares changed hands. CEO Stephane Bancel told Bloomberg TV the company won’t invest in new late-stage vaccine trials, pointing to growing resistance from U.S. officials. He cautioned that the U.S. market is becoming less dependable. “You cannot make a return on investment if you don’t have access to the U.S. market,” Bancel said.
Moderna stock jumps again as Merck cancer vaccine data keeps MRNA rally running
Moderna shares climbed 7.7% to $53.65 Thursday morning, extending gains fueled by fresh long-term data on its experimental personalized cancer vaccine, created in partnership with Merck.
Moderna stock (MRNA) steadies in premarket after 16% surge on Merck cancer-vaccine data
Moderna shares were flat at $49.81 in premarket trading on Thursday, after the stock jumped 15.8% in the previous session.
Merck (MRK) stock ends higher on long-term Keytruda cancer-vaccine data; Guardant pact and earnings ahead
Merck & Co’s stock ended Tuesday 0.57% higher, closing at $109.45, supported by long-term data on a personalized melanoma vaccine it’s working on with Moderna, which helped steady investor sentiment as the session wrapped up.
Merck stock barely budges after five-year Moderna vaccine data keeps Keytruda trade in play
Merck & Co shares held steady on Tuesday following news that the company's personalized cancer vaccine, developed with Moderna, continued to lower the risk of melanoma recurrence and death when used alongside Keytruda. By 2:02 p.m. EST, Merck was down just 0.01% at $108.82, with the stock fluctuating between $107.06 and $109.11.
Moderna stock price pops 6% into the weekend — here’s what traders are watching next for MRNA
Moderna’s stock climbed 6.3% Friday, closing at $41.83 as the rally that’s been choppy all week gained traction. Since January 12, shares have surged roughly 24%, boosted by a 17% jump on January 13, followed by a short pullback on January 15.
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook
Pfizer Inc. shares fell 0.6% to $25.42 in late-morning trading on Thursday, extending a choppy start to the year for the drugmaker’s stock.
Moderna stock (MRNA) slips in premarket after 17% surge — here’s what investors are watching next
Moderna shares fell roughly 1% in early trading Wednesday, following a strong jump the previous session. The stock stood at $39.20, down 40 cents from Tuesday’s close of $39.60.
Moderna stock jumps 12% after $1.9 billion 2025 sales view — what investors watch next
Moderna shares were up $3.97, or 11.7%, at $37.81 by late morning in New York, lifting the vaccine maker to one of the stronger movers in biotech trading.
Stock Market Today 13.01.2026
{“@context”:”https://schema.org”,”@type”:”LiveBlogPosting”,”@id”:”https://ts2.tech/en/stock-market-today-13-01-2026/#live”,”headline”:”Stock Market Today 13.01.2026″,”description”:”Live rolling coverage of stock markets, macro data, and major moves.”,”datePublished”:”2026-01-13T00:00:02-05:00″,”dateModified”:”2026-01-13T23:58:31-05:00″,”coverageStartTime”:”2026-01-13T00:00:02-05:00″,”author”:{“@type”:”Organization”,”name”:”TechStock²”},”publisher”:{“@type”:”Organization”,”name”:”TechStock²”,”logo”:{“@type”:”ImageObject”,”url”:”https://ts2.tech/wp-content/uploads/2024/02/cropped-ts2-logo-google.png”}},”inLanguage”:”en-US”,”liveBlogUpdate”:[{“@type”:”BlogPosting”,”@id”:”https://ts2.tech/en/stock-market-today-13-01-2026/#live/u/58d39bd3a041910c”,”headline”:”WHSP Holdings Insider Buying Reaches AU$3.4 Million, Led by Robert Millner”,”articleBody”:”WHSP Holdings Limited (ASX: SOL) saw insider buying over the past 12 months, led by Robert Millner with an AU$3.4 million purchase at AU$34.48 a share. The current price is about AU$38.00, suggesting purchases near the prevailing level. There were no insider sales in the period. Insiders own 5.4% of the company, worth around AU$782 million at latest prices, a sign of alignment with other shareholders. While such activity isnu0027t the sole predictor of returns, it can
Moderna stock slides as $1.9 billion sales view fails to calm investors (MRNA)
Moderna shares dropped roughly 4% on Monday following the release of updated revenue and expense forecasts ahead of a healthcare investor event. The stock fell $1.38 to $32.92, after starting the day at $34.40 and fluctuating between $35.77 and $32.81.
Moderna (MRNA) stock slips after $1.9B 2025 revenue view and cost cuts — what to watch next
Moderna shares dropped about 2% to $33.60 early Monday after the biotech forecasted around $1.9 billion in revenue for 2025 and lowered its GAAP operating-expense forecast for that year—the U.S. accounting standard. The stock swung between $35.77 and $33.33 in a volatile session.
Pfizer stock gains early as UBS starts coverage; Bayer mRNA lawsuit adds fresh risk
Pfizer shares rose about 0.9% to $25.67 in morning trade on Wednesday, even as investors weighed a new patent lawsuit tied to its COVID-19 vaccine and a cautious call from UBS.
S&P 500 2026 Forecast: 7,490 Target Meets a Data Test as Earnings Season Nears
Strategists polled by Reuters see the S&P 500 at 7,490 by end-2026, implying gains of just over 9% from end-2025 as investors weigh Fed succession, election risk and the durability of the AI boom. A slim majority—56%—also forecast a market correction in the coming months. “The most under-appreciated tail risk for 2026 is that the Fed eases monetary policy more than economic conditions justify, inadvertently reigniting inflation,” said Lale Akoner, a global market strategist at eToro. Reuters
Dow Jones futures tread water near 50,000 as jobs data looms after record close
Dow Jones futures were little changed on Wednesday, with the March e-mini contract up 5 points, or 0.01%, at 49,726 by 5:35 a.m. ET. Futures are contracts that track an index before the cash market opens. Investing.com
Moderna stock slides premarket after 11% surge on flu vaccine filings — what investors watch next
Moderna shares fell 1.4% to $35.15 in premarket trading on Wednesday, after jumping 10.9% in the previous session to close at $35.66. The stock hit an intraday high of $36.26 on Tuesday, with about 20.2 million shares traded. StockAnalysis
Dow Jones breaks above 49,000 in record close as chip-led rally rolls on
The Dow Jones Industrial Average closed above 49,000 for the first time on Tuesday, extending Wall Street’s early-year run as technology shares drove broad gains. The Dow added 484.90 points, or 1%, to 49,462.08; the S&P 500 rose 0.6% to 6,944.82 and the Nasdaq climbed 0.6% to 23,547.17. AP News